Activity of Sorafenib in Salivary Gland Cancer

NCT01703455 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Salivary Gland Cancer

Interventions

DRUG: Sorafenib

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano